Friday, 18 Aug 2017

You are here

Mycophenolate and Steroids in Neuropsychiatric Lupus

Beyond diagnosis, management of neuropsychiatric lupus (NPSLE) can be challenging. Moreover, there are scant studies addressing optimal management. In this issue of Clinical Rheumatology, researchers show the efficacy of mycophenolate mofetil (MMF) and deflazacort in NPSLE.

They identified 140 patients with NPSLE; 88 fulfilled the inclusion criteria. Most were young (25.51 ± 7.82 years) and female, and the median duration of follow-up was 33 months (3–129 months).

Seizures were the most common NPSLE manifestation (42%). After removing patients antiphospholipid syndrome, it was shown that the remaining 70 patients improved 87% with therapy.

At last follow-up, 97.1% with detailed data had improved, while 2 patients had relapsed on this regimen. Side effects were significantly more common in patients on prednisolone as compared to those on deflazacort.

In patients with NPSLE, MMF along with tapering steroids is an efficacious combo in inducing remission and preventing relapse of disease.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Duration of Azathioprine Maintenance in AAV Does Not Alter Relapse Rates

A European multicentre study examined whether the duration of azathioprine (AZA) maintenance therapy in ANCA-associated vasculitis patients would influence the relapse rate during long-term follow-up.

H1N1 Vaccination Triggers TLR Activation and Autoantibody Production in DMARD-naïve pSS

Increased morbidity and mortality from infectious causes in patients with autoimmune disorders has led to the overall consensus that vaccination of such patients is important and should be widely promoted in clinical practice. However, the autoimmune-biased immune system of the patient with rheumatic disease and use of immunosuppressive drugs tend to affect response to vaccination.

Lupus Hospitalizations are Common

Patients with systemic lupus erythematosus (SLE) incur substantial morbidity and complications that may lead to hospitalizations and increased cost of lupus care. Researchers from the University Health Network in Toronto have published a review of SLE hospitalizations showing thta while commone (for either infection or lupus activity), only 2.8% of hospitalizations resulted in death.

Increased Pulmonary Embolism Risk in Lupus Patients

Systemic lupus erythematosus (SLE) poses numerous vascular risks, many of which are thought to be autoantibody mediated.

A retrospective population-based analysis was done to determine the association of SLE and plumonary embolism (PE) using the National Hospital Discharge Survey data, a representative sample of hospital discharges throughout the United States.

Tubulointerstitial Damage in Lupus Predicts ESRD Progression

The presence of tubulointerstitial damage (TID) may provide a potential window for early intervention in lupus nephritis (LN) to ward off end-stage renal disease (ESRD), according to a data analysis.